nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0201	0.126	CbGbCtD
Ruxolitinib—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0189	0.119	CbGbCtD
Ruxolitinib—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0189	0.119	CbGbCtD
Ruxolitinib—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0171	0.107	CbGbCtD
Ruxolitinib—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0171	0.107	CbGbCtD
Ruxolitinib—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0148	0.0925	CbGbCtD
Ruxolitinib—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0143	0.0898	CbGbCtD
Ruxolitinib—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.013	0.0812	CbGbCtD
Ruxolitinib—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.013	0.0812	CbGbCtD
Ruxolitinib—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0124	0.0779	CbGbCtD
Ruxolitinib—Contusion—Delavirdine—acquired immunodeficiency syndrome	0.0024	0.00794	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Amprenavir—acquired immunodeficiency syndrome	0.00232	0.00767	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Efavirenz—acquired immunodeficiency syndrome	0.00231	0.00766	CcSEcCtD
Ruxolitinib—Bone pain—Efavirenz—acquired immunodeficiency syndrome	0.00229	0.00756	CcSEcCtD
Ruxolitinib—Bone pain—Delavirdine—acquired immunodeficiency syndrome	0.00219	0.00724	CcSEcCtD
Ruxolitinib—PLK1—Trifluridine—Zidovudine—acquired immunodeficiency syndrome	0.00218	0.246	CbGdCrCtD
Ruxolitinib—PLK1—Trifluridine—Stavudine—acquired immunodeficiency syndrome	0.00218	0.246	CbGdCrCtD
Ruxolitinib—Neutropenia—Amprenavir—acquired immunodeficiency syndrome	0.00213	0.00703	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Nelfinavir—acquired immunodeficiency syndrome	0.00209	0.00691	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Ritonavir—acquired immunodeficiency syndrome	0.00205	0.00678	CcSEcCtD
Ruxolitinib—Bone pain—Ritonavir—acquired immunodeficiency syndrome	0.00202	0.00669	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Saquinavir—acquired immunodeficiency syndrome	0.00197	0.00652	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Amprenavir—acquired immunodeficiency syndrome	0.00192	0.00634	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Nevirapine—acquired immunodeficiency syndrome	0.0019	0.00629	CcSEcCtD
Ruxolitinib—Hypercholesterolaemia—Lamivudine—acquired immunodeficiency syndrome	0.00188	0.00622	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Nelfinavir—acquired immunodeficiency syndrome	0.00184	0.00609	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Abacavir—acquired immunodeficiency syndrome	0.00181	0.00598	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Didanosine—acquired immunodeficiency syndrome	0.00175	0.00578	CcSEcCtD
Ruxolitinib—Neutropenia—Nevirapine—acquired immunodeficiency syndrome	0.00174	0.00576	CcSEcCtD
Ruxolitinib—Neutropenia—Nelfinavir—acquired immunodeficiency syndrome	0.00169	0.00558	CcSEcCtD
Ruxolitinib—Neutropenia—Stavudine—acquired immunodeficiency syndrome	0.00168	0.00556	CcSEcCtD
Ruxolitinib—Neutropenia—Abacavir—acquired immunodeficiency syndrome	0.00166	0.00548	CcSEcCtD
Ruxolitinib—Weight decreased—Stavudine—acquired immunodeficiency syndrome	0.00163	0.00538	CcSEcCtD
Ruxolitinib—Malnutrition—Amprenavir—acquired immunodeficiency syndrome	0.00158	0.00524	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Nevirapine—acquired immunodeficiency syndrome	0.00157	0.0052	CcSEcCtD
Ruxolitinib—Flatulence—Amprenavir—acquired immunodeficiency syndrome	0.00156	0.00516	CcSEcCtD
Ruxolitinib—Urinary tract infection—Stavudine—acquired immunodeficiency syndrome	0.00156	0.00516	CcSEcCtD
Ruxolitinib—Haematuria—Stavudine—acquired immunodeficiency syndrome	0.00153	0.00506	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Nelfinavir—acquired immunodeficiency syndrome	0.00152	0.00503	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Delavirdine—acquired immunodeficiency syndrome	0.00152	0.00503	CcSEcCtD
Ruxolitinib—Epistaxis—Nelfinavir—acquired immunodeficiency syndrome	0.00152	0.00502	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Stavudine—acquired immunodeficiency syndrome	0.00152	0.00502	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Abacavir—acquired immunodeficiency syndrome	0.00149	0.00494	CcSEcCtD
Ruxolitinib—Pancytopenia—Zidovudine—acquired immunodeficiency syndrome	0.00148	0.00491	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Indinavir—acquired immunodeficiency syndrome	0.00148	0.00491	CcSEcCtD
Ruxolitinib—Neutropenia—Zidovudine—acquired immunodeficiency syndrome	0.00146	0.00484	CcSEcCtD
Ruxolitinib—Haemoglobin—Nelfinavir—acquired immunodeficiency syndrome	0.00145	0.0048	CcSEcCtD
Ruxolitinib—Haemorrhage—Nelfinavir—acquired immunodeficiency syndrome	0.00144	0.00478	CcSEcCtD
Ruxolitinib—Flatulence—Didanosine—acquired immunodeficiency syndrome	0.00142	0.00471	CcSEcCtD
Ruxolitinib—Weight decreased—Zidovudine—acquired immunodeficiency syndrome	0.00141	0.00468	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Ritonavir—acquired immunodeficiency syndrome	0.00141	0.00465	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Saquinavir—acquired immunodeficiency syndrome	0.00135	0.00448	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Amprenavir—acquired immunodeficiency syndrome	0.00134	0.00443	CcSEcCtD
Ruxolitinib—Anaemia—Didanosine—acquired immunodeficiency syndrome	0.00133	0.00441	CcSEcCtD
Ruxolitinib—Haematuria—Zidovudine—acquired immunodeficiency syndrome	0.00133	0.0044	CcSEcCtD
Ruxolitinib—Weight increased—Indinavir—acquired immunodeficiency syndrome	0.00132	0.00438	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Zidovudine—acquired immunodeficiency syndrome	0.00132	0.00436	CcSEcCtD
Ruxolitinib—Epistaxis—Zidovudine—acquired immunodeficiency syndrome	0.00131	0.00435	CcSEcCtD
Ruxolitinib—Pancytopenia—Efavirenz—acquired immunodeficiency syndrome	0.0013	0.00432	CcSEcCtD
Ruxolitinib—Nervous system disorder—Amprenavir—acquired immunodeficiency syndrome	0.00127	0.00419	CcSEcCtD
Ruxolitinib—Urinary tract infection—Indinavir—acquired immunodeficiency syndrome	0.00126	0.00417	CcSEcCtD
Ruxolitinib—Malnutrition—Nelfinavir—acquired immunodeficiency syndrome	0.00126	0.00416	CcSEcCtD
Ruxolitinib—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00126	0.00415	CcSEcCtD
Ruxolitinib—Malnutrition—Stavudine—acquired immunodeficiency syndrome	0.00125	0.00415	CcSEcCtD
Ruxolitinib—Pancytopenia—Delavirdine—acquired immunodeficiency syndrome	0.00125	0.00413	CcSEcCtD
Ruxolitinib—Flatulence—Nelfinavir—acquired immunodeficiency syndrome	0.00124	0.0041	CcSEcCtD
Ruxolitinib—Haematuria—Indinavir—acquired immunodeficiency syndrome	0.00124	0.00409	CcSEcCtD
Ruxolitinib—Flatulence—Stavudine—acquired immunodeficiency syndrome	0.00123	0.00409	CcSEcCtD
Ruxolitinib—Malnutrition—Abacavir—acquired immunodeficiency syndrome	0.00123	0.00408	CcSEcCtD
Ruxolitinib—Neutropenia—Delavirdine—acquired immunodeficiency syndrome	0.00123	0.00407	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Indinavir—acquired immunodeficiency syndrome	0.00123	0.00406	CcSEcCtD
Ruxolitinib—Infestation—Efavirenz—acquired immunodeficiency syndrome	0.00122	0.00405	CcSEcCtD
Ruxolitinib—Infestation NOS—Efavirenz—acquired immunodeficiency syndrome	0.00122	0.00405	CcSEcCtD
Ruxolitinib—PLK1—Cladribine—Abacavir—acquired immunodeficiency syndrome	0.00122	0.138	CbGdCrCtD
Ruxolitinib—Anaemia—Nevirapine—acquired immunodeficiency syndrome	0.0012	0.00397	CcSEcCtD
Ruxolitinib—Weight increased—Delavirdine—acquired immunodeficiency syndrome	0.0012	0.00396	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Saquinavir—acquired immunodeficiency syndrome	0.00119	0.00395	CcSEcCtD
Ruxolitinib—Infection—Didanosine—acquired immunodeficiency syndrome	0.00117	0.00387	CcSEcCtD
Ruxolitinib—Haemoglobin—Indinavir—acquired immunodeficiency syndrome	0.00117	0.00387	CcSEcCtD
Ruxolitinib—Haematuria—Efavirenz—acquired immunodeficiency syndrome	0.00117	0.00386	CcSEcCtD
Ruxolitinib—Haemorrhage—Indinavir—acquired immunodeficiency syndrome	0.00116	0.00385	CcSEcCtD
Ruxolitinib—Anaemia—Nelfinavir—acquired immunodeficiency syndrome	0.00116	0.00384	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Efavirenz—acquired immunodeficiency syndrome	0.00116	0.00383	CcSEcCtD
Ruxolitinib—Anaemia—Stavudine—acquired immunodeficiency syndrome	0.00116	0.00383	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Didanosine—acquired immunodeficiency syndrome	0.00115	0.00382	CcSEcCtD
Ruxolitinib—Anaemia—Abacavir—acquired immunodeficiency syndrome	0.00114	0.00378	CcSEcCtD
Ruxolitinib—Urinary tract infection—Delavirdine—acquired immunodeficiency syndrome	0.00114	0.00377	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Lamivudine—acquired immunodeficiency syndrome	0.00114	0.00377	CcSEcCtD
Ruxolitinib—Neutropenia—Ritonavir—acquired immunodeficiency syndrome	0.00114	0.00376	CcSEcCtD
Ruxolitinib—PLK4—blood—acquired immunodeficiency syndrome	0.00112	0.00371	CbGeAlD
Ruxolitinib—HIPK2—lymphoid tissue—acquired immunodeficiency syndrome	0.00112	0.0037	CbGeAlD
Ruxolitinib—PLK1—Floxuridine—Zidovudine—acquired immunodeficiency syndrome	0.00112	0.126	CbGdCrCtD
Ruxolitinib—PLK1—Floxuridine—Stavudine—acquired immunodeficiency syndrome	0.00112	0.126	CbGdCrCtD
Ruxolitinib—CAMK1—nervous system—acquired immunodeficiency syndrome	0.00112	0.00369	CbGeAlD
Ruxolitinib—TYK2—retina—acquired immunodeficiency syndrome	0.00112	0.00369	CbGeAlD
Ruxolitinib—Haematuria—Delavirdine—acquired immunodeficiency syndrome	0.00112	0.0037	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Amprenavir—acquired immunodeficiency syndrome	0.00112	0.00369	CcSEcCtD
Ruxolitinib—Fatigue—Amprenavir—acquired immunodeficiency syndrome	0.00111	0.00369	CcSEcCtD
Ruxolitinib—STK16—digestive system—acquired immunodeficiency syndrome	0.00111	0.00367	CbGeAlD
Ruxolitinib—Pancytopenia—Saquinavir—acquired immunodeficiency syndrome	0.00111	0.00368	CcSEcCtD
Ruxolitinib—HIPK2—digestive system—acquired immunodeficiency syndrome	0.00111	0.00366	CbGeAlD
Ruxolitinib—Epistaxis—Delavirdine—acquired immunodeficiency syndrome	0.00111	0.00366	CcSEcCtD
Ruxolitinib—CAMK1D—blood—acquired immunodeficiency syndrome	0.0011	0.00364	CbGeAlD
Ruxolitinib—MKNK2—retina—acquired immunodeficiency syndrome	0.0011	0.00364	CbGeAlD
Ruxolitinib—PRKCE—lymph node—acquired immunodeficiency syndrome	0.0011	0.00364	CbGeAlD
Ruxolitinib—Weight decreased—Ritonavir—acquired immunodeficiency syndrome	0.0011	0.00364	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Nevirapine—acquired immunodeficiency syndrome	0.0011	0.00363	CcSEcCtD
Ruxolitinib—PLK1—brain—acquired immunodeficiency syndrome	0.0011	0.00361	CbGeAlD
Ruxolitinib—RPS6KA6—brain—acquired immunodeficiency syndrome	0.0011	0.00361	CbGeAlD
Ruxolitinib—MAST1—brain—acquired immunodeficiency syndrome	0.0011	0.00361	CbGeAlD
Ruxolitinib—JAK1—bone marrow—acquired immunodeficiency syndrome	0.00109	0.00361	CbGeAlD
Ruxolitinib—Neutropenia—Saquinavir—acquired immunodeficiency syndrome	0.00109	0.00362	CcSEcCtD
Ruxolitinib—Malnutrition—Zidovudine—acquired immunodeficiency syndrome	0.00109	0.0036	CcSEcCtD
Ruxolitinib—JAK1—spinal cord—acquired immunodeficiency syndrome	0.00109	0.00359	CbGeAlD
Ruxolitinib—DCLK1—spinal cord—acquired immunodeficiency syndrome	0.00109	0.00359	CbGeAlD
Ruxolitinib—PLK4—bone marrow—acquired immunodeficiency syndrome	0.00109	0.00359	CbGeAlD
Ruxolitinib—MARK2—nervous system—acquired immunodeficiency syndrome	0.00109	0.00358	CbGeAlD
Ruxolitinib—TAOK2—lung—acquired immunodeficiency syndrome	0.00109	0.00358	CbGeAlD
Ruxolitinib—DAPK2—blood—acquired immunodeficiency syndrome	0.00108	0.00356	CbGeAlD
Ruxolitinib—CAMK1—central nervous system—acquired immunodeficiency syndrome	0.00108	0.00355	CbGeAlD
Ruxolitinib—Flatulence—Zidovudine—acquired immunodeficiency syndrome	0.00107	0.00355	CcSEcCtD
Ruxolitinib—CLK2—lymphoid tissue—acquired immunodeficiency syndrome	0.00107	0.00352	CbGeAlD
Ruxolitinib—Weight increased—Saquinavir—acquired immunodeficiency syndrome	0.00106	0.00352	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Nelfinavir—acquired immunodeficiency syndrome	0.00106	0.00352	CcSEcCtD
Ruxolitinib—STK16—blood—acquired immunodeficiency syndrome	0.00106	0.0035	CbGeAlD
Ruxolitinib—Pancytopenia—Lamivudine—acquired immunodeficiency syndrome	0.00106	0.00351	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Stavudine—acquired immunodeficiency syndrome	0.00106	0.00351	CcSEcCtD
Ruxolitinib—RPS6KA6—lymph node—acquired immunodeficiency syndrome	0.00106	0.00349	CbGeAlD
Ruxolitinib—PLK1—lymph node—acquired immunodeficiency syndrome	0.00106	0.00349	CbGeAlD
Ruxolitinib—Weight decreased—Saquinavir—acquired immunodeficiency syndrome	0.00106	0.0035	CcSEcCtD
Ruxolitinib—Urinary tract infection—Ritonavir—acquired immunodeficiency syndrome	0.00105	0.00349	CcSEcCtD
Ruxolitinib—JAK1—vagina—acquired immunodeficiency syndrome	0.00105	0.00346	CbGeAlD
Ruxolitinib—DCLK1—vagina—acquired immunodeficiency syndrome	0.00105	0.00346	CbGeAlD
Ruxolitinib—MARK2—central nervous system—acquired immunodeficiency syndrome	0.00105	0.00345	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Abacavir—acquired immunodeficiency syndrome	0.00104	0.00345	CcSEcCtD
Ruxolitinib—DAPK2—bone marrow—acquired immunodeficiency syndrome	0.00104	0.00344	CbGeAlD
Ruxolitinib—Neutropenia—Lamivudine—acquired immunodeficiency syndrome	0.00104	0.00345	CcSEcCtD
Ruxolitinib—Infestation NOS—Saquinavir—acquired immunodeficiency syndrome	0.00104	0.00345	CcSEcCtD
Ruxolitinib—Infestation—Saquinavir—acquired immunodeficiency syndrome	0.00104	0.00345	CcSEcCtD
Ruxolitinib—DAPK2—spinal cord—acquired immunodeficiency syndrome	0.00104	0.00343	CbGeAlD
Ruxolitinib—Nervous system disorder—Nevirapine—acquired immunodeficiency syndrome	0.00104	0.00344	CcSEcCtD
Ruxolitinib—DCLK3—brain—acquired immunodeficiency syndrome	0.00104	0.00343	CbGeAlD
Ruxolitinib—Thrombocytopenia—Nevirapine—acquired immunodeficiency syndrome	0.00104	0.00343	CcSEcCtD
Ruxolitinib—ROCK1—lymphoid tissue—acquired immunodeficiency syndrome	0.00103	0.00341	CbGeAlD
Ruxolitinib—Haematuria—Ritonavir—acquired immunodeficiency syndrome	0.00103	0.00342	CcSEcCtD
Ruxolitinib—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00103	0.0034	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Ritonavir—acquired immunodeficiency syndrome	0.00102	0.00339	CcSEcCtD
Ruxolitinib—CAMK1D—vagina—acquired immunodeficiency syndrome	0.00102	0.00337	CbGeAlD
Ruxolitinib—Epistaxis—Ritonavir—acquired immunodeficiency syndrome	0.00102	0.00338	CcSEcCtD
Ruxolitinib—ROCK1—digestive system—acquired immunodeficiency syndrome	0.00102	0.00337	CbGeAlD
Ruxolitinib—HIPK2—spinal cord—acquired immunodeficiency syndrome	0.00102	0.00335	CbGeAlD
Ruxolitinib—DAPK3—blood—acquired immunodeficiency syndrome	0.00101	0.00335	CbGeAlD
Ruxolitinib—Urinary tract infection—Saquinavir—acquired immunodeficiency syndrome	0.00101	0.00335	CcSEcCtD
Ruxolitinib—Malnutrition—Indinavir—acquired immunodeficiency syndrome	0.00101	0.00335	CcSEcCtD
Ruxolitinib—DYRK1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00101	0.00333	CbGeAlD
Ruxolitinib—Anaemia—Zidovudine—acquired immunodeficiency syndrome	0.00101	0.00333	CcSEcCtD
Ruxolitinib—BMPR2—lymphoid tissue—acquired immunodeficiency syndrome	0.001	0.00332	CbGeAlD
Ruxolitinib—Thrombocytopenia—Nelfinavir—acquired immunodeficiency syndrome	0.001	0.00332	CcSEcCtD
Ruxolitinib—CLK2—blood—acquired immunodeficiency syndrome	0.001	0.00331	CbGeAlD
Ruxolitinib—Nervous system disorder—Stavudine—acquired immunodeficiency syndrome	0.001	0.00332	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Stavudine—acquired immunodeficiency syndrome	0.001	0.00331	CcSEcCtD
Ruxolitinib—Infection—Abacavir—acquired immunodeficiency syndrome	0.001	0.00331	CcSEcCtD
Ruxolitinib—DAPK2—vagina—acquired immunodeficiency syndrome	0.001	0.0033	CbGeAlD
Ruxolitinib—Flatulence—Indinavir—acquired immunodeficiency syndrome	0.000998	0.0033	CcSEcCtD
Ruxolitinib—JAK3—lung—acquired immunodeficiency syndrome	0.000997	0.00329	CbGeAlD
Ruxolitinib—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000997	0.0033	CcSEcCtD
Ruxolitinib—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.000993	0.00329	CcSEcCtD
Ruxolitinib—BMPR2—digestive system—acquired immunodeficiency syndrome	0.000993	0.00328	CbGeAlD
Ruxolitinib—JAK1—lung—acquired immunodeficiency syndrome	0.000991	0.00327	CbGeAlD
Ruxolitinib—DCLK1—lung—acquired immunodeficiency syndrome	0.000991	0.00327	CbGeAlD
Ruxolitinib—Nervous system disorder—Abacavir—acquired immunodeficiency syndrome	0.000988	0.00327	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Abacavir—acquired immunodeficiency syndrome	0.000987	0.00326	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Saquinavir—acquired immunodeficiency syndrome	0.000986	0.00326	CcSEcCtD
Ruxolitinib—PLK4—lung—acquired immunodeficiency syndrome	0.000985	0.00325	CbGeAlD
Ruxolitinib—Epistaxis—Saquinavir—acquired immunodeficiency syndrome	0.000984	0.00326	CcSEcCtD
Ruxolitinib—STK16—vagina—acquired immunodeficiency syndrome	0.000983	0.00324	CbGeAlD
Ruxolitinib—TYK2—skin of body—acquired immunodeficiency syndrome	0.000981	0.00324	CbGeAlD
Ruxolitinib—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.000979	0.00324	CcSEcCtD
Ruxolitinib—Haemoglobin—Ritonavir—acquired immunodeficiency syndrome	0.000978	0.00324	CcSEcCtD
Ruxolitinib—DAPK3—spinal cord—acquired immunodeficiency syndrome	0.000977	0.00322	CbGeAlD
Ruxolitinib—ROCK1—blood—acquired immunodeficiency syndrome	0.000974	0.00321	CbGeAlD
Ruxolitinib—Haemorrhage—Ritonavir—acquired immunodeficiency syndrome	0.000973	0.00322	CcSEcCtD
Ruxolitinib—CLK2—bone marrow—acquired immunodeficiency syndrome	0.000972	0.00321	CbGeAlD
Ruxolitinib—CAMK1D—lung—acquired immunodeficiency syndrome	0.000967	0.00319	CbGeAlD
Ruxolitinib—PHKG2—lung—acquired immunodeficiency syndrome	0.000962	0.00317	CbGeAlD
Ruxolitinib—Malnutrition—Efavirenz—acquired immunodeficiency syndrome	0.000957	0.00317	CcSEcCtD
Ruxolitinib—DAPK2—lung—acquired immunodeficiency syndrome	0.000945	0.00312	CbGeAlD
Ruxolitinib—Flatulence—Efavirenz—acquired immunodeficiency syndrome	0.000943	0.00312	CcSEcCtD
Ruxolitinib—Haemoglobin—Saquinavir—acquired immunodeficiency syndrome	0.000941	0.00311	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Lamivudine—acquired immunodeficiency syndrome	0.000941	0.00311	CcSEcCtD
Ruxolitinib—DAPK3—vagina—acquired immunodeficiency syndrome	0.00094	0.0031	CbGeAlD
Ruxolitinib—Epistaxis—Lamivudine—acquired immunodeficiency syndrome	0.000939	0.00311	CcSEcCtD
Ruxolitinib—Haemorrhage—Saquinavir—acquired immunodeficiency syndrome	0.000936	0.0031	CcSEcCtD
Ruxolitinib—Anaemia—Indinavir—acquired immunodeficiency syndrome	0.000936	0.0031	CcSEcCtD
Ruxolitinib—Body temperature increased—Didanosine—acquired immunodeficiency syndrome	0.000931	0.00308	CcSEcCtD
Ruxolitinib—CLK2—vagina—acquired immunodeficiency syndrome	0.000931	0.00307	CbGeAlD
Ruxolitinib—STK16—lung—acquired immunodeficiency syndrome	0.00093	0.00307	CbGeAlD
Ruxolitinib—Asthenia—Amprenavir—acquired immunodeficiency syndrome	0.000927	0.00307	CcSEcCtD
Ruxolitinib—HIPK2—lung—acquired immunodeficiency syndrome	0.000925	0.00305	CbGeAlD
Ruxolitinib—JAK3—nervous system—acquired immunodeficiency syndrome	0.000924	0.00305	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000921	0.00305	CcSEcCtD
Ruxolitinib—JAK1—nervous system—acquired immunodeficiency syndrome	0.000918	0.00303	CbGeAlD
Ruxolitinib—DCLK1—nervous system—acquired immunodeficiency syndrome	0.000918	0.00303	CbGeAlD
Ruxolitinib—Malnutrition—Delavirdine—acquired immunodeficiency syndrome	0.000916	0.00303	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Nevirapine—acquired immunodeficiency syndrome	0.000915	0.00303	CcSEcCtD
Ruxolitinib—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000914	0.00303	CcSEcCtD
Ruxolitinib—PLK3—brain—acquired immunodeficiency syndrome	0.000914	0.00302	CbGeAlD
Ruxolitinib—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000913	0.00302	CcSEcCtD
Ruxolitinib—MAP3K19—lung—acquired immunodeficiency syndrome	0.000906	0.00299	CbGeAlD
Ruxolitinib—NUAK2—blood—acquired immunodeficiency syndrome	0.000904	0.00298	CbGeAlD
Ruxolitinib—Flatulence—Delavirdine—acquired immunodeficiency syndrome	0.000902	0.00299	CcSEcCtD
Ruxolitinib—CAMK1D—nervous system—acquired immunodeficiency syndrome	0.000896	0.00296	CbGeAlD
Ruxolitinib—TAOK3—retina—acquired immunodeficiency syndrome	0.000893	0.00295	CbGeAlD
Ruxolitinib—JAK2—skin of body—acquired immunodeficiency syndrome	0.000892	0.00294	CbGeAlD
Ruxolitinib—PHKG2—nervous system—acquired immunodeficiency syndrome	0.000891	0.00294	CbGeAlD
Ruxolitinib—JAK3—central nervous system—acquired immunodeficiency syndrome	0.000889	0.00293	CbGeAlD
Ruxolitinib—DAPK3—lung—acquired immunodeficiency syndrome	0.000889	0.00293	CbGeAlD
Ruxolitinib—CAMK2G—digestive system—acquired immunodeficiency syndrome	0.000888	0.00293	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000886	0.00293	CcSEcCtD
Ruxolitinib—Anaemia—Efavirenz—acquired immunodeficiency syndrome	0.000885	0.00293	CcSEcCtD
Ruxolitinib—JAK1—central nervous system—acquired immunodeficiency syndrome	0.000884	0.00292	CbGeAlD
Ruxolitinib—DCLK1—central nervous system—acquired immunodeficiency syndrome	0.000884	0.00292	CbGeAlD
Ruxolitinib—PLK3—lymph node—acquired immunodeficiency syndrome	0.000883	0.00291	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000883	0.00292	CcSEcCtD
Ruxolitinib—LTK—brain—acquired immunodeficiency syndrome	0.000883	0.00291	CbGeAlD
Ruxolitinib—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000882	0.00292	CcSEcCtD
Ruxolitinib—CLK2—lung—acquired immunodeficiency syndrome	0.000881	0.00291	CbGeAlD
Ruxolitinib—BMPR2—vagina—acquired immunodeficiency syndrome	0.000877	0.00289	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—acquired immunodeficiency syndrome	0.000874	0.00289	CbGeAlD
Ruxolitinib—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000872	0.00288	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Zidovudine—acquired immunodeficiency syndrome	0.00087	0.00288	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.00087	0.00288	CcSEcCtD
Ruxolitinib—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000869	0.00287	CcSEcCtD
Ruxolitinib—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000863	0.00286	CcSEcCtD
Ruxolitinib—CAMK1D—central nervous system—acquired immunodeficiency syndrome	0.000862	0.00285	CbGeAlD
Ruxolitinib—STK16—nervous system—acquired immunodeficiency syndrome	0.000861	0.00284	CbGeAlD
Ruxolitinib—MAP3K3—skin of body—acquired immunodeficiency syndrome	0.00086	0.00284	CbGeAlD
Ruxolitinib—PHKG2—central nervous system—acquired immunodeficiency syndrome	0.000857	0.00283	CbGeAlD
Ruxolitinib—HIPK2—nervous system—acquired immunodeficiency syndrome	0.000857	0.00283	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000856	0.00283	CcSEcCtD
Ruxolitinib—CAMK1—brain—acquired immunodeficiency syndrome	0.000855	0.00282	CbGeAlD
Ruxolitinib—ROCK1—lung—acquired immunodeficiency syndrome	0.000853	0.00282	CbGeAlD
Ruxolitinib—LTK—lymph node—acquired immunodeficiency syndrome	0.000853	0.00282	CbGeAlD
Ruxolitinib—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.000847	0.0028	CcSEcCtD
Ruxolitinib—Anaemia—Delavirdine—acquired immunodeficiency syndrome	0.000846	0.0028	CcSEcCtD
Ruxolitinib—CAMK2G—blood—acquired immunodeficiency syndrome	0.000846	0.00279	CbGeAlD
Ruxolitinib—BMP2K—blood—acquired immunodeficiency syndrome	0.000846	0.00279	CbGeAlD
Ruxolitinib—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000845	0.0028	CcSEcCtD
Ruxolitinib—MAP3K19—nervous system—acquired immunodeficiency syndrome	0.000839	0.00277	CbGeAlD
Ruxolitinib—LRRK2—blood—acquired immunodeficiency syndrome	0.000839	0.00277	CbGeAlD
Ruxolitinib—NUAK2—vagina—acquired immunodeficiency syndrome	0.000838	0.00276	CbGeAlD
Ruxolitinib—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000837	0.00277	CcSEcCtD
Ruxolitinib—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.000834	0.00276	CcSEcCtD
Ruxolitinib—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000834	0.00276	CcSEcCtD
Ruxolitinib—DYRK1A—lung—acquired immunodeficiency syndrome	0.000832	0.00275	CbGeAlD
Ruxolitinib—MARK2—brain—acquired immunodeficiency syndrome	0.00083	0.00274	CbGeAlD
Ruxolitinib—STK16—central nervous system—acquired immunodeficiency syndrome	0.000829	0.00274	CbGeAlD
Ruxolitinib—BMPR2—lung—acquired immunodeficiency syndrome	0.000829	0.00274	CbGeAlD
Ruxolitinib—CAMK1—lymph node—acquired immunodeficiency syndrome	0.000826	0.00273	CbGeAlD
Ruxolitinib—HIPK2—central nervous system—acquired immunodeficiency syndrome	0.000825	0.00272	CbGeAlD
Ruxolitinib—DAPK3—nervous system—acquired immunodeficiency syndrome	0.000823	0.00272	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—acquired immunodeficiency syndrome	0.000819	0.0027	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—acquired immunodeficiency syndrome	0.000819	0.0027	CbGeAlD
Ruxolitinib—MAP3K2—lymphoid tissue—acquired immunodeficiency syndrome	0.000817	0.00269	CbGeAlD
Ruxolitinib—CLK2—nervous system—acquired immunodeficiency syndrome	0.000815	0.00269	CbGeAlD
Ruxolitinib—BMP2K—spinal cord—acquired immunodeficiency syndrome	0.000815	0.00269	CbGeAlD
Ruxolitinib—CAMK2G—spinal cord—acquired immunodeficiency syndrome	0.000815	0.00269	CbGeAlD
Ruxolitinib—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000815	0.0027	CcSEcCtD
Ruxolitinib—LRRK2—bone marrow—acquired immunodeficiency syndrome	0.000812	0.00268	CbGeAlD
Ruxolitinib—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000811	0.00268	CcSEcCtD
Ruxolitinib—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000811	0.00268	CcSEcCtD
Ruxolitinib—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00081	0.00268	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000809	0.00268	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000809	0.00268	CcSEcCtD
Ruxolitinib—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000809	0.00268	CcSEcCtD
Ruxolitinib—MAP3K19—central nervous system—acquired immunodeficiency syndrome	0.000808	0.00267	CbGeAlD
Ruxolitinib—LRRK2—spinal cord—acquired immunodeficiency syndrome	0.000808	0.00267	CbGeAlD
Ruxolitinib—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000803	0.00266	CcSEcCtD
Ruxolitinib—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000803	0.00266	CcSEcCtD
Ruxolitinib—MARK2—lymph node—acquired immunodeficiency syndrome	0.000802	0.00265	CbGeAlD
Ruxolitinib—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000797	0.00264	CcSEcCtD
Ruxolitinib—TYK2—lymphoid tissue—acquired immunodeficiency syndrome	0.000794	0.00262	CbGeAlD
Ruxolitinib—DAPK3—central nervous system—acquired immunodeficiency syndrome	0.000793	0.00261	CbGeAlD
Ruxolitinib—NUAK2—lung—acquired immunodeficiency syndrome	0.000792	0.00261	CbGeAlD
Ruxolitinib—ROCK1—nervous system—acquired immunodeficiency syndrome	0.00079	0.00261	CbGeAlD
Ruxolitinib—CLK2—central nervous system—acquired immunodeficiency syndrome	0.000785	0.00259	CbGeAlD
Ruxolitinib—TYK2—digestive system—acquired immunodeficiency syndrome	0.000785	0.00259	CbGeAlD
Ruxolitinib—BMP2K—vagina—acquired immunodeficiency syndrome	0.000784	0.00259	CbGeAlD
Ruxolitinib—CAMK2G—vagina—acquired immunodeficiency syndrome	0.000784	0.00259	CbGeAlD
Ruxolitinib—MKNK2—lymphoid tissue—acquired immunodeficiency syndrome	0.000784	0.00259	CbGeAlD
Ruxolitinib—Anaemia—Ritonavir—acquired immunodeficiency syndrome	0.000783	0.00259	CcSEcCtD
Ruxolitinib—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000778	0.00257	CcSEcCtD
Ruxolitinib—LRRK2—vagina—acquired immunodeficiency syndrome	0.000777	0.00257	CbGeAlD
Ruxolitinib—MKNK2—digestive system—acquired immunodeficiency syndrome	0.000774	0.00256	CbGeAlD
Ruxolitinib—DYRK1A—nervous system—acquired immunodeficiency syndrome	0.000771	0.00254	CbGeAlD
Ruxolitinib—MAP3K2—blood—acquired immunodeficiency syndrome	0.000768	0.00254	CbGeAlD
Ruxolitinib—TAOK2—brain—acquired immunodeficiency syndrome	0.000768	0.00253	CbGeAlD
Ruxolitinib—BMPR2—nervous system—acquired immunodeficiency syndrome	0.000768	0.00253	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000767	0.00254	CcSEcCtD
Ruxolitinib—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000766	0.00254	CcSEcCtD
Ruxolitinib—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.000766	0.00254	CcSEcCtD
Ruxolitinib—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000766	0.00253	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000765	0.00253	CcSEcCtD
Ruxolitinib—RET—lymphoid tissue—acquired immunodeficiency syndrome	0.000765	0.00252	CbGeAlD
Ruxolitinib—MAP3K7—blood—acquired immunodeficiency syndrome	0.000761	0.00251	CbGeAlD
Ruxolitinib—ROCK1—central nervous system—acquired immunodeficiency syndrome	0.000761	0.00251	CbGeAlD
Ruxolitinib—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.00076	0.00251	CcSEcCtD
Ruxolitinib—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000759	0.00251	CcSEcCtD
Ruxolitinib—RET—digestive system—acquired immunodeficiency syndrome	0.000755	0.00249	CbGeAlD
Ruxolitinib—Anaemia—Saquinavir—acquired immunodeficiency syndrome	0.000753	0.00249	CcSEcCtD
Ruxolitinib—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000749	0.00248	CcSEcCtD
Ruxolitinib—TYK2—blood—acquired immunodeficiency syndrome	0.000748	0.00247	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—acquired immunodeficiency syndrome	0.000744	0.00245	CbGeAlD
Ruxolitinib—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000743	0.00246	CcSEcCtD
Ruxolitinib—TAOK2—lymph node—acquired immunodeficiency syndrome	0.000742	0.00245	CbGeAlD
Ruxolitinib—DYRK1A—central nervous system—acquired immunodeficiency syndrome	0.000742	0.00245	CbGeAlD
Ruxolitinib—CAMK2G—lung—acquired immunodeficiency syndrome	0.000742	0.00245	CbGeAlD
Ruxolitinib—BMP2K—lung—acquired immunodeficiency syndrome	0.000742	0.00245	CbGeAlD
Ruxolitinib—BMPR2—central nervous system—acquired immunodeficiency syndrome	0.000739	0.00244	CbGeAlD
Ruxolitinib—Headache—Didanosine—acquired immunodeficiency syndrome	0.000738	0.00244	CcSEcCtD
Ruxolitinib—IRAK1—blood—acquired immunodeficiency syndrome	0.000738	0.00243	CbGeAlD
Ruxolitinib—MKNK2—blood—acquired immunodeficiency syndrome	0.000738	0.00243	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—acquired immunodeficiency syndrome	0.000737	0.00243	CbGeAlD
Ruxolitinib—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000736	0.00244	CcSEcCtD
Ruxolitinib—LRRK2—lung—acquired immunodeficiency syndrome	0.000735	0.00243	CbGeAlD
Ruxolitinib—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000734	0.00243	CcSEcCtD
Ruxolitinib—MAP3K7—spinal cord—acquired immunodeficiency syndrome	0.000733	0.00242	CbGeAlD
Ruxolitinib—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000732	0.00242	CcSEcCtD
Ruxolitinib—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000726	0.0024	CcSEcCtD
Ruxolitinib—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000726	0.0024	CcSEcCtD
Ruxolitinib—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000724	0.00239	CcSEcCtD
Ruxolitinib—TYK2—bone marrow—acquired immunodeficiency syndrome	0.000723	0.00239	CbGeAlD
Ruxolitinib—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000723	0.00239	CcSEcCtD
Ruxolitinib—JAK2—lymphoid tissue—acquired immunodeficiency syndrome	0.000723	0.00238	CbGeAlD
Ruxolitinib—TYK2—spinal cord—acquired immunodeficiency syndrome	0.00072	0.00238	CbGeAlD
Ruxolitinib—RET—blood—acquired immunodeficiency syndrome	0.00072	0.00237	CbGeAlD
Ruxolitinib—Anaemia—Lamivudine—acquired immunodeficiency syndrome	0.000719	0.00238	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000716	0.00237	CcSEcCtD
Ruxolitinib—IRAK1—bone marrow—acquired immunodeficiency syndrome	0.000714	0.00236	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—acquired immunodeficiency syndrome	0.000714	0.00236	CbGeAlD
Ruxolitinib—JAK2—digestive system—acquired immunodeficiency syndrome	0.000714	0.00236	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000714	0.00236	CcSEcCtD
Ruxolitinib—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000713	0.00236	CcSEcCtD
Ruxolitinib—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000713	0.00236	CcSEcCtD
Ruxolitinib—MKNK2—spinal cord—acquired immunodeficiency syndrome	0.000711	0.00235	CbGeAlD
Ruxolitinib—JAK3—brain—acquired immunodeficiency syndrome	0.000706	0.00233	CbGeAlD
Ruxolitinib—MAP3K7—vagina—acquired immunodeficiency syndrome	0.000706	0.00233	CbGeAlD
Ruxolitinib—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000703	0.00233	CcSEcCtD
Ruxolitinib—JAK1—brain—acquired immunodeficiency syndrome	0.000701	0.00231	CbGeAlD
Ruxolitinib—DCLK1—brain—acquired immunodeficiency syndrome	0.000701	0.00231	CbGeAlD
Ruxolitinib—PLK4—brain—acquired immunodeficiency syndrome	0.000697	0.0023	CbGeAlD
Ruxolitinib—RET—spinal cord—acquired immunodeficiency syndrome	0.000693	0.00229	CbGeAlD
Ruxolitinib—TYK2—vagina—acquired immunodeficiency syndrome	0.000693	0.00229	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000689	0.00228	CcSEcCtD
Ruxolitinib—BMP2K—nervous system—acquired immunodeficiency syndrome	0.000687	0.00227	CbGeAlD
Ruxolitinib—CAMK2G—nervous system—acquired immunodeficiency syndrome	0.000687	0.00227	CbGeAlD
Ruxolitinib—CAMK1D—brain—acquired immunodeficiency syndrome	0.000685	0.00226	CbGeAlD
Ruxolitinib—MKNK2—vagina—acquired immunodeficiency syndrome	0.000684	0.00226	CbGeAlD
Ruxolitinib—JAK3—lymph node—acquired immunodeficiency syndrome	0.000682	0.00225	CbGeAlD
Ruxolitinib—LRRK2—nervous system—acquired immunodeficiency syndrome	0.000681	0.00225	CbGeAlD
Ruxolitinib—PHKG2—brain—acquired immunodeficiency syndrome	0.000681	0.00225	CbGeAlD
Ruxolitinib—JAK2—blood—acquired immunodeficiency syndrome	0.00068	0.00224	CbGeAlD
Ruxolitinib—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000678	0.00224	CcSEcCtD
Ruxolitinib—JAK1—lymph node—acquired immunodeficiency syndrome	0.000678	0.00224	CbGeAlD
Ruxolitinib—DCLK1—lymph node—acquired immunodeficiency syndrome	0.000678	0.00224	CbGeAlD
Ruxolitinib—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000678	0.00224	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000677	0.00224	CcSEcCtD
Ruxolitinib—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000676	0.00224	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000674	0.00223	CcSEcCtD
Ruxolitinib—MAP3K2—lung—acquired immunodeficiency syndrome	0.000674	0.00222	CbGeAlD
Ruxolitinib—PLK4—lymph node—acquired immunodeficiency syndrome	0.000674	0.00222	CbGeAlD
Ruxolitinib—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000673	0.00223	CcSEcCtD
Ruxolitinib—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000671	0.00222	CcSEcCtD
Ruxolitinib—DAPK2—brain—acquired immunodeficiency syndrome	0.000669	0.00221	CbGeAlD
Ruxolitinib—MAP3K7—lung—acquired immunodeficiency syndrome	0.000667	0.0022	CbGeAlD
Ruxolitinib—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000666	0.0022	CcSEcCtD
Ruxolitinib—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000664	0.0022	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—acquired immunodeficiency syndrome	0.000662	0.00218	CbGeAlD
Ruxolitinib—CAMK2G—central nervous system—acquired immunodeficiency syndrome	0.000661	0.00218	CbGeAlD
Ruxolitinib—BMP2K—central nervous system—acquired immunodeficiency syndrome	0.000661	0.00218	CbGeAlD
Ruxolitinib—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000661	0.00219	CcSEcCtD
Ruxolitinib—STK16—brain—acquired immunodeficiency syndrome	0.000658	0.00217	CbGeAlD
Ruxolitinib—JAK2—bone marrow—acquired immunodeficiency syndrome	0.000658	0.00217	CbGeAlD
Ruxolitinib—PHKG2—lymph node—acquired immunodeficiency syndrome	0.000658	0.00217	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000657	0.00218	CcSEcCtD
Ruxolitinib—LRRK2—central nervous system—acquired immunodeficiency syndrome	0.000656	0.00216	CbGeAlD
Ruxolitinib—MAP3K3—blood—acquired immunodeficiency syndrome	0.000655	0.00216	CbGeAlD
Ruxolitinib—TYK2—lung—acquired immunodeficiency syndrome	0.000655	0.00216	CbGeAlD
Ruxolitinib—JAK2—spinal cord—acquired immunodeficiency syndrome	0.000655	0.00216	CbGeAlD
Ruxolitinib—HIPK2—brain—acquired immunodeficiency syndrome	0.000655	0.00216	CbGeAlD
Ruxolitinib—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000654	0.00216	CcSEcCtD
Ruxolitinib—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000652	0.00216	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000651	0.00216	CcSEcCtD
Ruxolitinib—MKNK2—lung—acquired immunodeficiency syndrome	0.000647	0.00213	CbGeAlD
Ruxolitinib—IRAK1—lung—acquired immunodeficiency syndrome	0.000647	0.00213	CbGeAlD
Ruxolitinib—DAPK2—lymph node—acquired immunodeficiency syndrome	0.000647	0.00213	CbGeAlD
Ruxolitinib—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000646	0.00214	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000645	0.00213	CcSEcCtD
Ruxolitinib—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000644	0.00213	CcSEcCtD
Ruxolitinib—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000643	0.00213	CcSEcCtD
Ruxolitinib—MAP3K19—brain—acquired immunodeficiency syndrome	0.000642	0.00212	CbGeAlD
Ruxolitinib—Headache—Stavudine—acquired immunodeficiency syndrome	0.000641	0.00212	CcSEcCtD
Ruxolitinib—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000638	0.00211	CcSEcCtD
Ruxolitinib—STK16—lymph node—acquired immunodeficiency syndrome	0.000636	0.0021	CbGeAlD
Ruxolitinib—TAOK3—lymphoid tissue—acquired immunodeficiency syndrome	0.000635	0.0021	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—acquired immunodeficiency syndrome	0.000634	0.00209	CbGeAlD
Ruxolitinib—HIPK2—lymph node—acquired immunodeficiency syndrome	0.000633	0.00209	CbGeAlD
Ruxolitinib—MAP3K3—spinal cord—acquired immunodeficiency syndrome	0.000632	0.00208	CbGeAlD
Ruxolitinib—Headache—Abacavir—acquired immunodeficiency syndrome	0.000631	0.00209	CcSEcCtD
Ruxolitinib—Infection—Lamivudine—acquired immunodeficiency syndrome	0.00063	0.00209	CcSEcCtD
Ruxolitinib—JAK2—vagina—acquired immunodeficiency syndrome	0.00063	0.00208	CbGeAlD
Ruxolitinib—DAPK3—brain—acquired immunodeficiency syndrome	0.000629	0.00208	CbGeAlD
Ruxolitinib—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000629	0.00208	CcSEcCtD
Ruxolitinib—TAOK3—digestive system—acquired immunodeficiency syndrome	0.000627	0.00207	CbGeAlD
Ruxolitinib—MAP3K2—nervous system—acquired immunodeficiency syndrome	0.000624	0.00206	CbGeAlD
Ruxolitinib—CLK2—brain—acquired immunodeficiency syndrome	0.000623	0.00206	CbGeAlD
Ruxolitinib—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000622	0.00206	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.000621	0.00206	CcSEcCtD
Ruxolitinib—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000617	0.00204	CcSEcCtD
Ruxolitinib—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000616	0.00204	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—acquired immunodeficiency syndrome	0.000608	0.00201	CbGeAlD
Ruxolitinib—MAP3K3—vagina—acquired immunodeficiency syndrome	0.000608	0.002	CbGeAlD
Ruxolitinib—TYK2—nervous system—acquired immunodeficiency syndrome	0.000607	0.002	CbGeAlD
Ruxolitinib—ROCK1—brain—acquired immunodeficiency syndrome	0.000604	0.00199	CbGeAlD
Ruxolitinib—CLK2—lymph node—acquired immunodeficiency syndrome	0.000602	0.00199	CbGeAlD
Ruxolitinib—MAP3K2—central nervous system—acquired immunodeficiency syndrome	0.000601	0.00198	CbGeAlD
Ruxolitinib—MKNK2—nervous system—acquired immunodeficiency syndrome	0.000599	0.00198	CbGeAlD
Ruxolitinib—TAOK3—blood—acquired immunodeficiency syndrome	0.000598	0.00197	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000597	0.00197	CcSEcCtD
Ruxolitinib—JAK2—lung—acquired immunodeficiency syndrome	0.000596	0.00197	CbGeAlD
Ruxolitinib—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000596	0.00197	CcSEcCtD
Ruxolitinib—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000593	0.00196	CcSEcCtD
Ruxolitinib—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000591	0.00195	CcSEcCtD
Ruxolitinib—DYRK1A—brain—acquired immunodeficiency syndrome	0.000589	0.00194	CbGeAlD
Ruxolitinib—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000588	0.00195	CcSEcCtD
Ruxolitinib—BMPR2—brain—acquired immunodeficiency syndrome	0.000587	0.00194	CbGeAlD
Ruxolitinib—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000585	0.00194	CcSEcCtD
Ruxolitinib—TYK2—central nervous system—acquired immunodeficiency syndrome	0.000584	0.00193	CbGeAlD
Ruxolitinib—RET—nervous system—acquired immunodeficiency syndrome	0.000584	0.00193	CbGeAlD
Ruxolitinib—TAOK3—bone marrow—acquired immunodeficiency syndrome	0.000578	0.00191	CbGeAlD
Ruxolitinib—MKNK2—central nervous system—acquired immunodeficiency syndrome	0.000577	0.0019	CbGeAlD
Ruxolitinib—TAOK3—spinal cord—acquired immunodeficiency syndrome	0.000576	0.0019	CbGeAlD
Ruxolitinib—MAP3K3—lung—acquired immunodeficiency syndrome	0.000575	0.0019	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000574	0.0019	CcSEcCtD
Ruxolitinib—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000574	0.0019	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—acquired immunodeficiency syndrome	0.000569	0.00188	CbGeAlD
Ruxolitinib—BMPR2—lymph node—acquired immunodeficiency syndrome	0.000567	0.00187	CbGeAlD
Ruxolitinib—RET—central nervous system—acquired immunodeficiency syndrome	0.000562	0.00186	CbGeAlD
Ruxolitinib—NUAK2—brain—acquired immunodeficiency syndrome	0.000561	0.00185	CbGeAlD
Ruxolitinib—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00056	0.00185	CcSEcCtD
Ruxolitinib—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000557	0.00184	CcSEcCtD
Ruxolitinib—TAOK3—vagina—acquired immunodeficiency syndrome	0.000554	0.00183	CbGeAlD
Ruxolitinib—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000553	0.00183	CcSEcCtD
Ruxolitinib—JAK2—nervous system—acquired immunodeficiency syndrome	0.000552	0.00182	CbGeAlD
Ruxolitinib—PLK1—Gemcitabine—Lamivudine—acquired immunodeficiency syndrome	0.00055	0.062	CbGdCrCtD
Ruxolitinib—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000548	0.00181	CcSEcCtD
Ruxolitinib—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000547	0.00181	CcSEcCtD
Ruxolitinib—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000547	0.00181	CcSEcCtD
Ruxolitinib—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000546	0.00181	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—acquired immunodeficiency syndrome	0.000542	0.00179	CbGeAlD
Ruxolitinib—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000536	0.00177	CcSEcCtD
Ruxolitinib—MAP3K3—nervous system—acquired immunodeficiency syndrome	0.000532	0.00176	CbGeAlD
Ruxolitinib—JAK2—central nervous system—acquired immunodeficiency syndrome	0.000532	0.00175	CbGeAlD
Ruxolitinib—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000529	0.00175	CcSEcCtD
Ruxolitinib—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000526	0.00174	CcSEcCtD
Ruxolitinib—CAMK2G—brain—acquired immunodeficiency syndrome	0.000525	0.00173	CbGeAlD
Ruxolitinib—BMP2K—brain—acquired immunodeficiency syndrome	0.000525	0.00173	CbGeAlD
Ruxolitinib—TAOK3—lung—acquired immunodeficiency syndrome	0.000524	0.00173	CbGeAlD
Ruxolitinib—LRRK2—brain—acquired immunodeficiency syndrome	0.00052	0.00172	CbGeAlD
Ruxolitinib—Headache—Indinavir—acquired immunodeficiency syndrome	0.000518	0.00171	CcSEcCtD
Ruxolitinib—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000517	0.00171	CcSEcCtD
Ruxolitinib—MAP3K3—central nervous system—acquired immunodeficiency syndrome	0.000512	0.00169	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—acquired immunodeficiency syndrome	0.000507	0.00167	CbGeAlD
Ruxolitinib—BMP2K—lymph node—acquired immunodeficiency syndrome	0.000507	0.00167	CbGeAlD
Ruxolitinib—PLK1—Cytarabine—Lamivudine—acquired immunodeficiency syndrome	0.000505	0.0569	CbGdCrCtD
Ruxolitinib—LRRK2—lymph node—acquired immunodeficiency syndrome	0.000503	0.00166	CbGeAlD
Ruxolitinib—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000502	0.00166	CcSEcCtD
Ruxolitinib—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000496	0.00164	CcSEcCtD
Ruxolitinib—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000496	0.00164	CbGeAlD
Ruxolitinib—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000494	0.00164	CcSEcCtD
Ruxolitinib—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000489	0.00162	CcSEcCtD
Ruxolitinib—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000489	0.00162	CcSEcCtD
Ruxolitinib—TAOK3—nervous system—acquired immunodeficiency syndrome	0.000485	0.0016	CbGeAlD
Ruxolitinib—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000477	0.00158	CcSEcCtD
Ruxolitinib—MAP3K2—brain—acquired immunodeficiency syndrome	0.000477	0.00157	CbGeAlD
Ruxolitinib—MAP3K7—brain—acquired immunodeficiency syndrome	0.000472	0.00156	CbGeAlD
Ruxolitinib—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000471	0.00156	CcSEcCtD
Ruxolitinib—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000468	0.00155	CcSEcCtD
Ruxolitinib—TAOK3—central nervous system—acquired immunodeficiency syndrome	0.000467	0.00154	CbGeAlD
Ruxolitinib—TYK2—brain—acquired immunodeficiency syndrome	0.000464	0.00153	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—acquired immunodeficiency syndrome	0.000461	0.00152	CbGeAlD
Ruxolitinib—MKNK2—brain—acquired immunodeficiency syndrome	0.000458	0.00151	CbGeAlD
Ruxolitinib—IRAK1—brain—acquired immunodeficiency syndrome	0.000458	0.00151	CbGeAlD
Ruxolitinib—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000457	0.00151	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—acquired immunodeficiency syndrome	0.000456	0.00151	CbGeAlD
Ruxolitinib—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000455	0.00151	CcSEcCtD
Ruxolitinib—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000449	0.00149	CcSEcCtD
Ruxolitinib—TYK2—lymph node—acquired immunodeficiency syndrome	0.000448	0.00148	CbGeAlD
Ruxolitinib—RET—brain—acquired immunodeficiency syndrome	0.000446	0.00147	CbGeAlD
Ruxolitinib—IRAK1—lymph node—acquired immunodeficiency syndrome	0.000442	0.00146	CbGeAlD
Ruxolitinib—MKNK2—lymph node—acquired immunodeficiency syndrome	0.000442	0.00146	CbGeAlD
Ruxolitinib—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00044	0.00146	CcSEcCtD
Ruxolitinib—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000433	0.00143	CcSEcCtD
Ruxolitinib—RET—lymph node—acquired immunodeficiency syndrome	0.000431	0.00142	CbGeAlD
Ruxolitinib—JAK2—brain—acquired immunodeficiency syndrome	0.000422	0.00139	CbGeAlD
Ruxolitinib—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00042	0.00139	CcSEcCtD
Ruxolitinib—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000417	0.00138	CcSEcCtD
Ruxolitinib—JAK2—lymph node—acquired immunodeficiency syndrome	0.000408	0.00135	CbGeAlD
Ruxolitinib—MAP3K3—brain—acquired immunodeficiency syndrome	0.000407	0.00134	CbGeAlD
Ruxolitinib—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000398	0.00132	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—acquired immunodeficiency syndrome	0.000393	0.0013	CbGeAlD
Ruxolitinib—TAOK3—brain—acquired immunodeficiency syndrome	0.000371	0.00122	CbGeAlD
Ruxolitinib—TAOK3—lymph node—acquired immunodeficiency syndrome	0.000358	0.00118	CbGeAlD
Ruxolitinib—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000191	0.000629	CbGeAlD
Ruxolitinib—CYP3A4—blood—acquired immunodeficiency syndrome	0.000182	0.000599	CbGeAlD
Ruxolitinib—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000147	0.000486	CbGeAlD
Ruxolitinib—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000142	0.000468	CbGeAlD
Ruxolitinib—TYK2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	5.34e-05	0.000236	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.33e-05	0.000236	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.33e-05	0.000236	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.32e-05	0.000235	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD8A—acquired immunodeficiency syndrome	5.32e-05	0.000235	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CSF2—acquired immunodeficiency syndrome	5.32e-05	0.000235	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.31e-05	0.000234	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	5.29e-05	0.000234	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	5.27e-05	0.000233	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—CD4—acquired immunodeficiency syndrome	5.24e-05	0.000232	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.23e-05	0.000231	CbGpPWpGaD
Ruxolitinib—MAP3K7—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	5.22e-05	0.000231	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNA1—acquired immunodeficiency syndrome	5.17e-05	0.000228	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HLA-B—acquired immunodeficiency syndrome	5.11e-05	0.000226	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	5.11e-05	0.000226	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	5.09e-05	0.000225	CbGpPWpGaD
Ruxolitinib—JAK1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	5.06e-05	0.000223	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD79A—acquired immunodeficiency syndrome	5.02e-05	0.000222	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNA1—acquired immunodeficiency syndrome	5.02e-05	0.000222	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	4.97e-05	0.00022	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	4.91e-05	0.000217	CbGpPWpGaD
Ruxolitinib—JAK2—Toll-Like Receptors Cascades—IL6—acquired immunodeficiency syndrome	4.9e-05	0.000216	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	4.9e-05	0.000216	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.89e-05	0.000216	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.89e-05	0.000216	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.88e-05	0.000216	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD79A—acquired immunodeficiency syndrome	4.87e-05	0.000215	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNA1—acquired immunodeficiency syndrome	4.86e-05	0.000215	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CXCR4—acquired immunodeficiency syndrome	4.84e-05	0.000214	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL2—acquired immunodeficiency syndrome	4.81e-05	0.000213	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.81e-05	0.000212	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.8e-05	0.000212	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.78e-05	0.000211	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.78e-05	0.000211	CbGpPWpGaD
Ruxolitinib—TYK2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	4.77e-05	0.000211	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4.73e-05	0.000209	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD79A—acquired immunodeficiency syndrome	4.72e-05	0.000209	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	4.69e-05	0.000207	CbGpPWpGaD
Ruxolitinib—PRKCE—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	4.66e-05	0.000206	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.62e-05	0.000204	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	4.61e-05	0.000204	CbGpPWpGaD
Ruxolitinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.61e-05	0.000204	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.59e-05	0.000203	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.59e-05	0.000203	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.53e-05	0.0002	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.51e-05	0.000199	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.51e-05	0.000199	CbGpPWpGaD
Ruxolitinib—JAK1—Axon guidance—IL6—acquired immunodeficiency syndrome	4.5e-05	0.000199	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CCR5—acquired immunodeficiency syndrome	4.49e-05	0.000198	CbGpPWpGaD
Ruxolitinib—ROCK1—Axon guidance—IL6—acquired immunodeficiency syndrome	4.42e-05	0.000195	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	4.42e-05	0.000195	CbGpPWpGaD
Ruxolitinib—JAK2—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	4.4e-05	0.000195	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	4.38e-05	0.000194	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.36e-05	0.000193	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	4.36e-05	0.000193	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IFNG—acquired immunodeficiency syndrome	4.35e-05	0.000192	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	4.34e-05	0.000192	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	4.34e-05	0.000192	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 signaling—IL6—acquired immunodeficiency syndrome	4.34e-05	0.000192	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	4.33e-05	0.000191	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.3e-05	0.00019	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	4.26e-05	0.000188	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	4.23e-05	0.000187	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CCR2—acquired immunodeficiency syndrome	4.22e-05	0.000187	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD4—acquired immunodeficiency syndrome	4.21e-05	0.000186	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.1e-05	0.000181	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD40LG—acquired immunodeficiency syndrome	4.09e-05	0.000181	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00018	CbGpPWpGaD
Ruxolitinib—JAK2—DAP12 interactions—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00018	CbGpPWpGaD
Ruxolitinib—JAK2—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	4.08e-05	0.00018	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	4.06e-05	0.000179	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	4.05e-05	0.000179	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CSF2—acquired immunodeficiency syndrome	4.04e-05	0.000179	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD8A—acquired immunodeficiency syndrome	4.04e-05	0.000179	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	4.01e-05	0.000177	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	4e-05	0.000177	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	3.99e-05	0.000176	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IFNG—acquired immunodeficiency syndrome	3.99e-05	0.000176	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.99e-05	0.000176	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.98e-05	0.000176	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.98e-05	0.000176	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD40LG—acquired immunodeficiency syndrome	3.97e-05	0.000175	CbGpPWpGaD
Ruxolitinib—JAK3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.94e-05	0.000174	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.93e-05	0.000174	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD8A—acquired immunodeficiency syndrome	3.92e-05	0.000173	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CSF2—acquired immunodeficiency syndrome	3.92e-05	0.000173	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—TNF—acquired immunodeficiency syndrome	3.91e-05	0.000173	CbGpPWpGaD
Ruxolitinib—PRKCE—Innate Immune System—IL6—acquired immunodeficiency syndrome	3.9e-05	0.000173	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IFNG—acquired immunodeficiency syndrome	3.9e-05	0.000172	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-B—acquired immunodeficiency syndrome	3.89e-05	0.000172	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CD4—acquired immunodeficiency syndrome	3.88e-05	0.000172	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.87e-05	0.000171	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL2—acquired immunodeficiency syndrome	3.87e-05	0.000171	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.86e-05	0.000171	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.85e-05	0.00017	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD4—acquired immunodeficiency syndrome	3.85e-05	0.00017	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD40LG—acquired immunodeficiency syndrome	3.85e-05	0.00017	CbGpPWpGaD
Ruxolitinib—IRAK1—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	3.84e-05	0.00017	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD8A—acquired immunodeficiency syndrome	3.81e-05	0.000168	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CSF2—acquired immunodeficiency syndrome	3.81e-05	0.000168	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNA1—acquired immunodeficiency syndrome	3.8e-05	0.000168	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.78e-05	0.000167	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-B—acquired immunodeficiency syndrome	3.78e-05	0.000167	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD4—acquired immunodeficiency syndrome	3.76e-05	0.000166	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CD4—acquired immunodeficiency syndrome	3.75e-05	0.000166	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	3.73e-05	0.000165	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.71e-05	0.000164	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—ALB—acquired immunodeficiency syndrome	3.7e-05	0.000163	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD79A—acquired immunodeficiency syndrome	3.69e-05	0.000163	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IFNG—acquired immunodeficiency syndrome	3.67e-05	0.000162	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	3.67e-05	0.000162	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CXCR4—acquired immunodeficiency syndrome	3.66e-05	0.000162	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-B—acquired immunodeficiency syndrome	3.66e-05	0.000162	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.65e-05	0.000161	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.64e-05	0.000161	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	3.62e-05	0.00016	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	3.62e-05	0.00016	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	3.6e-05	0.000159	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.6e-05	0.000159	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.58e-05	0.000158	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—IL6—acquired immunodeficiency syndrome	3.58e-05	0.000158	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.57e-05	0.000158	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD4—acquired immunodeficiency syndrome	3.55e-05	0.000157	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL2—acquired immunodeficiency syndrome	3.54e-05	0.000157	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.49e-05	0.000154	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.49e-05	0.000154	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.49e-05	0.000154	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.49e-05	0.000154	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.49e-05	0.000154	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL2—acquired immunodeficiency syndrome	3.46e-05	0.000153	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.44e-05	0.000152	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.43e-05	0.000152	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.39e-05	0.00015	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.39e-05	0.00015	CbGpPWpGaD
Ruxolitinib—JAK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.39e-05	0.00015	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.38e-05	0.000149	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.33e-05	0.000147	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—IL6—acquired immunodeficiency syndrome	3.32e-05	0.000147	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CCR5—acquired immunodeficiency syndrome	3.31e-05	0.000146	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	3.3e-05	0.000146	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.28e-05	0.000145	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.28e-05	0.000145	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	3.28e-05	0.000145	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL2—acquired immunodeficiency syndrome	3.27e-05	0.000144	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	3.26e-05	0.000144	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—IL6—acquired immunodeficiency syndrome	3.23e-05	0.000143	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.21e-05	0.000142	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IFNG—acquired immunodeficiency syndrome	3.16e-05	0.00014	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—IL6—acquired immunodeficiency syndrome	3.16e-05	0.000139	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.14e-05	0.000139	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.09e-05	0.000137	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.07e-05	0.000136	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD4—acquired immunodeficiency syndrome	3.05e-05	0.000135	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.02e-05	0.000134	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.02e-05	0.000133	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD40LG—acquired immunodeficiency syndrome	3.01e-05	0.000133	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—IL2—acquired immunodeficiency syndrome	3e-05	0.000132	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.98e-05	0.000132	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD8A—acquired immunodeficiency syndrome	2.97e-05	0.000131	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CSF2—acquired immunodeficiency syndrome	2.97e-05	0.000131	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.94e-05	0.00013	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD4—acquired immunodeficiency syndrome	2.93e-05	0.00013	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-B—acquired immunodeficiency syndrome	2.86e-05	0.000126	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.84e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—IL6—acquired immunodeficiency syndrome	2.83e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—acquired immunodeficiency syndrome	2.82e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL2—acquired immunodeficiency syndrome	2.81e-05	0.000124	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	2.78e-05	0.000123	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.73e-05	0.000121	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.66e-05	0.000118	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.65e-05	0.000117	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.61e-05	0.000115	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.58e-05	0.000114	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.57e-05	0.000113	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.57e-05	0.000113	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.54e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—IL6—acquired immunodeficiency syndrome	2.52e-05	0.000111	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CCR5—acquired immunodeficiency syndrome	2.51e-05	0.000111	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.5e-05	0.000111	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.5e-05	0.000111	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.5e-05	0.00011	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.49e-05	0.00011	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.46e-05	0.000109	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.43e-05	0.000107	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IFNG—acquired immunodeficiency syndrome	2.4e-05	0.000106	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.39e-05	0.000106	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	2.37e-05	0.000105	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IFNG—acquired immunodeficiency syndrome	2.33e-05	0.000103	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—acquired immunodeficiency syndrome	2.32e-05	0.000103	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.32e-05	0.000103	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—IL6—acquired immunodeficiency syndrome	2.27e-05	0.0001	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.27e-05	0.0001	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.26e-05	0.0001	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IFNG—acquired immunodeficiency syndrome	2.26e-05	0.0001	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—acquired immunodeficiency syndrome	2.25e-05	9.96e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.25e-05	9.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—TNF—acquired immunodeficiency syndrome	2.23e-05	9.83e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—acquired immunodeficiency syndrome	2.19e-05	9.66e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.16e-05	9.53e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL2—acquired immunodeficiency syndrome	2.14e-05	9.44e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.11e-05	9.33e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2.1e-05	9.28e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—IL6—acquired immunodeficiency syndrome	2.1e-05	9.28e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.09e-05	9.25e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—IL6—acquired immunodeficiency syndrome	2.08e-05	9.2e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—acquired immunodeficiency syndrome	2.08e-05	9.19e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL2—acquired immunodeficiency syndrome	2.07e-05	9.16e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	2.07e-05	9.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—IL6—acquired immunodeficiency syndrome	2.03e-05	8.99e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.03e-05	8.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL2—acquired immunodeficiency syndrome	2.01e-05	8.89e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.95e-05	8.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.92e-05	8.5e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—IL6—acquired immunodeficiency syndrome	1.92e-05	8.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.89e-05	8.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.82e-05	8.02e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.81e-05	7.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—acquired immunodeficiency syndrome	1.8e-05	7.94e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.79e-05	7.89e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.78e-05	7.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IFNG—acquired immunodeficiency syndrome	1.77e-05	7.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.76e-05	7.77e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.72e-05	7.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—acquired immunodeficiency syndrome	1.71e-05	7.55e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—acquired immunodeficiency syndrome	1.65e-05	7.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—acquired immunodeficiency syndrome	1.59e-05	7.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—acquired immunodeficiency syndrome	1.58e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL2—acquired immunodeficiency syndrome	1.57e-05	6.94e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—acquired immunodeficiency syndrome	1.52e-05	6.74e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.47e-05	6.5e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.38e-05	6.1e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.34e-05	5.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.33e-05	5.89e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.3e-05	5.75e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—acquired immunodeficiency syndrome	1.26e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.24e-05	5.48e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—acquired immunodeficiency syndrome	1.22e-05	5.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—acquired immunodeficiency syndrome	1.18e-05	5.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—acquired immunodeficiency syndrome	1.13e-05	4.97e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.07e-05	4.72e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.05e-05	4.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.02e-05	4.49e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.01e-05	4.47e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—acquired immunodeficiency syndrome	9.24e-06	4.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—acquired immunodeficiency syndrome	8.53e-06	3.77e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.12e-06	3.59e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.88e-06	3.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.64e-06	3.38e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.97e-06	2.64e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	4.24e-06	1.87e-05	CbGpPWpGaD
